These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37740238)

  • 1. Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes.
    Sleiman Y; Reiken S; Charrabi A; Jaffré F; Sittenfeld LR; Pasquié JL; Colombani S; Lerman BB; Chen S; Marks AR; Cheung JW; Evans T; Lacampagne A; Meli AC
    Stem Cell Res Ther; 2023 Sep; 14(1):266. PubMed ID: 37740238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling polymorphic ventricular tachycardia at rest using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Sleiman Y; Souidi M; Kumar R; Yang E; Jaffré F; Zhou T; Bernardin A; Reiken S; Cazorla O; Kajava AV; Moreau A; Pasquié JL; Marks AR; Lerman BB; Chen S; Cheung JW; Evans T; Lacampagne A; Meli AC
    EBioMedicine; 2020 Oct; 60():103024. PubMed ID: 32980690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-coupled polymorphic ventricular tachycardia at rest linked to a novel ryanodine receptor (RyR2) mutation: leaky RyR2 channels under non-stress conditions.
    Cheung JW; Meli AC; Xie W; Mittal S; Reiken S; Wronska A; Xu L; Steinberg JS; Markowitz SM; Iwai S; Lacampagne A; Lerman BB; Marks AR
    Int J Cardiol; 2015 Feb; 180():228-36. PubMed ID: 25463374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
    Zhang XH; Wei H; Xia Y; Morad M
    Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Translational Modifications and Diastolic Calcium Leak Associated to the Novel RyR2-D3638A Mutation Lead to CPVT in Patient-Specific hiPSC-Derived Cardiomyocytes.
    Acimovic I; Refaat MM; Moreau A; Salykin A; Reiken S; Sleiman Y; Souidi M; Přibyl J; Kajava AV; Richard S; Lu JT; Chevalier P; Skládal P; Dvořak P; Rotrekl V; Marks AR; Scheinman MM; Lacampagne A; Meli AC
    J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30413023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
    Pölönen RP; Swan H; Aalto-Setälä K
    Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
    Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
    Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ryanodine receptor dysfunction causes senescence and fibrosis in Duchenne dilated cardiomyopathy.
    Souidi M; Resta J; Dridi H; Sleiman Y; Reiken S; Formoso K; Colombani S; Amédro P; Meyer P; Charrabi A; Vincenti M; Liu Y; Soni RK; Lezoualc'h F; Stéphane Blot DVM; Rivier F; Cazorla O; Parini A; Marks AR; Mialet-Perez J; Lacampagne A; Meli AC
    J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):536-551. PubMed ID: 38221511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
    Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
    PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function, and prevents sudden arrhythmic death in failing hearts.
    Joshi P; Estes S; DeMazumder D; Knollmann BC; Dey S
    Elife; 2023 Dec; 12():. PubMed ID: 38078905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
    Bannister ML; MacLeod KT; George CH
    Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The H29D Mutation Does Not Enhance Cytosolic Ca2+ Activation of the Cardiac Ryanodine Receptor.
    Xiao Z; Guo W; Yuen SM; Wang R; Zhang L; Van Petegem F; Chen SR
    PLoS One; 2015; 10(9):e0139058. PubMed ID: 26405799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
    Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
    Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.